TEM

Tempus AI, Inc. Class A Common Stock

86.45 USD
-0.59
0.68%
At close Updated Sep 17, 4:00 PM EDT
Pre-market
After hours
87.95
+1.50
1.74%
1 day
-0.68%
5 days
8.85%
1 month
10.2%
3 months
23.31%
6 months
73.35%
Year to date
152.41%
1 year
75.6%
5 years
114.78%
10 years
114.78%
 

About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.

Employees: 2,400

0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

187% more first-time investments, than exits

New positions opened: 129 | Existing positions closed: 45

92% more call options, than puts

Call options by funds: $1.18B | Put options by funds: $614M

84% more capital invested

Capital invested by funds: $2.85B [Q1] → $5.24B (+$2.38B) [Q2]

63% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 73

28% more funds holding

Funds holding: 283 [Q1] → 363 (+80) [Q2]

13.67% more ownership

Funds ownership: 35.35% [Q1] → 49.02% (+13.67%) [Q2]

67% less funds holding in top 10

Funds holding in top 10: 15 [Q1] → 5 (-10) [Q2]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$68
21% downside
Avg. target
$79
8% downside
High target
$98
13% upside

5 analyst ratings

positive
80%
neutral
20%
negative
0%
HC Wainwright & Co.
Yi Chen
$98
Buy
Maintained
12 Sep 2025
BTIG
Mark Massaro
$85
Buy
Maintained
20 Aug 2025
Morgan Stanley
Tejas Savant
$68
Overweight
Maintained
12 Aug 2025
Guggenheim
Subbu Nambi
$75
Buy
Maintained
30 Jun 2025
B of A Securities
Michael Ryskin
$70
Neutral
Maintained
25 Jun 2025

Financial journalist opinion

Based on 30 articles about TEM published over the past 30 days

Positive
Zacks Investment Research
yesterday
TEM Strengthens Radiology Portfolio With Pixel's FDA Clearance
Tempus AI secures FDA clearance for its updated Pixel cardiac imaging platform, boosting radiology precision and efficiency.
TEM Strengthens Radiology Portfolio With Pixel's FDA Clearance
Neutral
PRNewsWire
2 days ago
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK , Sept. 15, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ: TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its US network of healthcare institutions.
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
Positive
Invezz
5 days ago
Tempus AI stock is cheap as Murrey Math Lines points to more gains
Tempus AI stock price surged to a record high on Wednesday after the healthcare-focused artificial intelligence company announced a major breakthrough from the Food and Drug Administration (FDA). It jumped to a high of $91, which coincided with the highest point in February this year.
Tempus AI stock is cheap as Murrey Math Lines points to more gains
Positive
Forbes
5 days ago
Tempus AI: Is TEM Stock A 10x Growth Story?
Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly accurate images of a patient's heart.
Tempus AI: Is TEM Stock A 10x Growth Story?
Positive
Zacks Investment Research
5 days ago
Tempus (TEM) Stock Jumps 13.6%: Will It Continue to Soar?
Tempus (TEM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Tempus (TEM) Stock Jumps 13.6%: Will It Continue to Soar?
Positive
The Motley Fool
6 days ago
Why Tempus AI Stock Soared Nearly 14% Higher Today
The stock of healthcare-focused artificial intelligence company Tempus AI (TEM 13.26%) was the cure for aching portfolios on Thursday. The company's share price ballooned by almost 14% on the back of a top regulator's decision about one of its products.
Why Tempus AI Stock Soared Nearly 14% Higher Today
Positive
Benzinga
6 days ago
Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging
On Thursday, Tempus AI, Inc. TEM received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform.
Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging
Positive
Investors Business Daily
6 days ago
Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA Move
Tempus AI stock jumped into a profit-taking zone Thursday after the FDA cleared its updated cardiac-imaging platform, Tempus Pixel.
Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA Move
Positive
Zacks Investment Research
6 days ago
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
Tempus AI's PurIST test secures clinical validation, helping personalize treatment choices for advanced pancreatic cancer patients.
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
Neutral
Business Wire
6 days ago
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device's capabilities for cardiac MR image analysis. Tempus Pixel provides advanced viewing and automated reporti.
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
Charts implemented using Lightweight Charts™